This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Institute of Nuclear Energy Research. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: **Chia-Yu Yu: Innovator in Radioactive Labeling Techniques**
Introduction
Chia-Yu Yu is a prominent inventor based in Taoyuan County, Taiwan. He has made significant contributions in the field of nuclear medicine, particularly with his innovative methods for preparing microspheres essential for medical applications.
Latest Patents
Chia-Yu Yu holds a unique patent titled "Method for making rhenium-186/188 labeled human serum albumin microspheres and kit for making the same and method for using the kit." This patent involves a novel approach to preparing rhenium-labeled human serum albumin (HSA) microspheres, utilizing Re(I)-tricarbonyl ions as precursors. The invention focuses on enhancing radioembolization techniques for treating liver tumors, demonstrating a strong potential for clinical application.
Career Highlights
Chia-Yu Yu is currently affiliated with the Institute of Nuclear Energy Research, under the Atomic Energy Council, Executive Yuan. His innovative work has positioned him as a key figure in the advancement of techniques that aid in the treatment of various medical conditions through improved radioisotope delivery systems.
Collaborations
Throughout his career, Chia-Yu Yu has collaborated with notable colleagues, including Te-Wei Lee and Su-Jung Chen. Their joint efforts highlight the importance of teamwork in the advancement of scientific research and innovations.
Conclusion
The contributions of Chia-Yu Yu in the realm of nuclear medicine illustrate the tremendous potential of innovative solutions in addressing critical healthcare challenges. His patent for rhenium-186/188 labeled HSA microspheres not only showcases his ingenuity but also paves the way for enhanced treatment modalities in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
